Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

tor antagonists in the treatment of hypertension in
patients aged > or = 65 years. Drugs Aging 26:751,
2009.
210. Sehgal AR. Overlap between whites and blacks in
response to antihypertensive drugs. Hypertension
43: 566, 2004.
211. Weir MR, Gray JM, Paster R, et al: Differing mechanisms
of action of angiotensin-converting enzyme
inhibition in black and white hypertensive patients.
Hypertension 25:124, 1995.
212. Agodoa LY, Appel L, Bakris GL, et al: Effect of
ramipril vs amlodipine on renal outcomes in hypertensive
nephrosclerosis: A randomized controlled
trial. JAMA 285:2719, 2001.
213. Whitworth JA; World Health Organization, International
Society of Hypertension Writing Group.
2003 World Health Organization (WHO)/International
Society of Hypertension (ISH) statement on
management of hypertension. J Hypertens 21:1983,
2003.
214. Zannad F: Trandolapril: how does it differ from
other angiotensin-converting enzyme Inhibitors.
Drugs 46 (Suppl 2):172, 1993.
215. Omboni S, Fogari R, Palatini P, et al: Reproducibility
and clinical value of the trough-to-peak ratio
of the antihypertensive effect. Evidence from the
Sample Study. Hypertension 32:424, 1998.
216. Izzo JL, Sica DA: Antihypertensive drugs: pharmacologic
principles and dosing effects. In: Izzo JL,
Sica DA, Black HR, eds. Hypertension Primer. 4th
ed. Philadelphia Lippincott, Williams & Wilkins,
2008:432–435.
217. Gradman AH, Lewin A, Bowling BT, et al: Comparative
effects of candesartan cilexetil and losartan in
patients with systemic hypertension. Candesartan
Versus Losartan Efficacy Comparison (CANDLE)
Study Group. Heart Dis 1:52, 1999.
218. Mancia G, Dell’Oro R, Turri C, Grassi G: Comparison
of angiotensin II receptor blockers: impact of
missed doses of candesartan cilexetil and losartan
in systemic hypertension. Am J Cardiol 84:28S,
1999.
219. Oparil S, Williams D, Chrysant SG, et al: Comparative
efficacy of olmesartan, losartan, valsartan, and
irbesartan in the control of essential hypertension.
J Clin Hypertens 3:283, 2001.
220. Vidt DG, White WB, Ripley E, et al: A forced titration
study of antihypertensive efficacy of candesartan
cilexetil in comparison to losartan: CLAIM
Study II. J Hum Hypertens 15:475, 2001.
221. Meredith PA: Clinical comparative trials of angiotensin
II type 1 (AT1)-receptor blockers. Blood
Press Suppl 3:11, 2001.
222. Oparil S: Are there meaningful differences in blood
References to Chapter 9 9-9
pressure control with current antihypertensive
agents. Am J Hypertens 15:14S, 2002.
223. Conlin PR, Spence JD, Williams B, et al: Angiotensin
II antagonists for hypertension: Are there differences
in efficacy. Am J Hypertens 13:418, 2000.
224. Fogari R, Mugellini A, Zoppi A, et al: A doubleblind
crossover study of the antihyper-tensive efficacy
of angiotensin II-receptor antagonists and
their activation of the renin-angiotensin system.
Curr Ther Res Clin Exp 61:669, 2000.
225. Hansson L: The relationship between dose and
antihypertensive effect for different AT1-receptor
blockers. Blood Press Suppl 3:33, 2001.
226. Veteran’s Administration Cooperative Study Group
on Antihypertensive Agents. Low-dose captopril
for the treatment of mild to moderate hypertension.
Hypertension 5 (Suppl III): 139, 1983.
227. Neutel JM, Black HR, Weber MA: Combination
therapy with diuretics: An evolution of understanding.
Am J Med 101:61S, 1996.
228. Sica DA: Rationale for fixed-dose combinations in
the treatment of hypertension: The cycle repeats.
Drugs 62:443, 2002.
229. Veteran Administration Cooperative Study Group
on Antihypertensive Agents. Racial differences in
response to low-dose captopril are abolished by the
addition of hydrochloro-thiazide. Br J Clin Pharmacol
14:97S, 1982.
230. Hansson L: Beta blockers with ACE inhibitors - a
logical combination. J Hum Hypertens 3:97, 1989.
231. Belz GG, Essig J, Erb K, et al: Pharmacokinetic and
pharmacodynamic interactions between the ACE
inhibitor cilazapril and beta-adrenoreceptor antagonist
propranolol in healthy subjects and in hypertensive
patients. Br J Clin Pharmacol 27 (Suppl
2): 317S, 1989.
232. Black HR, Sollins JS, Garofalo JL: The addition of
doxazosin to the therapeutic regimen of hypertensive
patients inadequately controlled with other
antihypertensive medications: A randomized, placebo-controlled
study. Am J Hypertens 13:468–474,
2000.
233. Frampton JE, Scott LJ. Amlodipine/valsartan single-pill
combination: a review of its use in the management
of hypertension. Am J Cardiovasc Drugs
9:309, 2009.
234. Frishman WH, Ram CV, McMahon FG, et al., for
the Benazepril/Amlodipine Study Group. Comparison
of amlodipine and benazepril monotherapy
to amlodipine plus benazepril in patients with systemic
hypertension: A randomized, double-blind,
placebo-controlled, parallel-group study. J Clin
Pharmacol 35:1060, 1995.
235. DeQuattro V, Lee D: Fixed-dose combination ther-